Dr. Mark Kirchhof

Dermatologist, Ottawa, ON

Dr. Mark Kirchhof is the Division Head of Dermatology in the Faculty of Medicine at the University of Ottawa and The Ottawa Hospital. After receiving his Bachelor of Science in molecular biology from McMaster University, Dr. Kirchhof completed his medical degree and PhD at Western University in London, Ontario. His PhD research involved studies of the signalling pathways important to immune system regulation. He then went on to complete his dermatology residency at the University of British Columbia in Vancouver, British Columbia.
Until August 2017, Dr. Kirchhof was the Education Director at Queen’s University in Kingston, Ontario, where he coordinated and led undergraduate, post-graduate and continuing medical education activities. He has published over 85 peer-reviewed papers and maintains a keen interest in clinical and bench-to-bedside research. He has been invited to speak at local, national and international meetings. His clinical interests are varied and he sees both pediatric and adult patients.

4:25 PM - 4:55 PM

FRI Apr 19

Name that Rash: Differentiating the dangerous from the mundane

The primary objective of this presentation is to have challenging discussion, polling, and reflection questions to help HCPs: Recognize some of the differences between GPP and skin conditions with similar presentations and provide realistic guidance on what they should do if they come across these diseases in their practice.

Learning Objectives:

  1. Recognize the signs and symptoms of generalized pustular psoriasis (GPP)
  2. Distinguish GPP from other skin conditions with similar presentations
  3. Choose treatment options to manage patients with these conditions

1:15 PM -1:45 PM

SAT Apr 20

Unlocking the potential, exploring OX40 signalling in atopic dermatitis (AD)


  • Investigate the role of OX40 expression and signaling in driving inflammation and chronicity in AD, highlighting its potential as a novel therapeutic target
  • Examine the clinical trial landscape focusing on the OX40 pathway in patients with moderate-to-severe AD

Amgen logo